Spdr S&P Pharmaceuticals Etf(XPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XPH Spdr S&P Pharmaceuticals Etf

Post-Mkt 09-29 17:28:10 EDT

66.09

-0.80

-1.20%

盘后66.09

+0.000.00%

16:15 EDT

High66.93	Low65.89	Vol155.10K
Open66.68	D1 Closing66.89	Amplitude1.55%
Mkt Cap545.26M	Tradable Cap545.26M	Total Shares8.25M
T/O10.25M	T/O Rate1.88%	Tradable Shares8.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"Spdr S&P Pharmaceuticals Etf","latestPrice":66.09,"timestamp":1790712000000,"preClose":66.89,"halted":0,"volume":155102,"hourTrading":{"tag":"盘后","latestPrice":66.09,"preClose":66.09,"latestTime":"16:15 EDT","volume":15,"amount":991.35,"timestamp":1790712900354,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011959934220361745,"floatShares":8250300,"shares":8250300,"eps":2.581957,"marketStatus":"Post-Mkt","change":-0.8,"latestTime":"09-29 17:28:10 EDT","open":66.68,"high":66.925,"low":65.89,"amount":10253112,"amplitude":0.015473,"askPrice":73.42,"askSize":100,"bidPrice":57.23,"bidSize":100,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790726400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":66.89,"sharesOutstanding":5750270,"nav":66.169885,"aum":539302424.92,"dividendRate":0.004149,"bidAskSpread":0.00179,"preHourTrading":{"tag":"盘前","latestPrice":66.89,"preClose":66.89,"latestTime":"07:56 EDT","volume":84,"amount":5618.76,"timestamp":1790682981101,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":66.09,"preClose":66.09,"latestTime":"16:15 EDT","volume":15,"amount":991.35,"timestamp":1790712900354,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.223455,"impliedVol":0.1362,"impliedVolPercentile":0.3586},"requestUrl":"/m/hq/s/XPH/tweets","defaultTab":"tweets","newsList":[{"id":"1188705505","title":"Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705505","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705505?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:03","pubTimestamp":1790647387,"startTime":"0","endTime":"0","summary":"Shares of Sino Biopharmaceutical (01177) climbed nearly 4%, rising 3.64% to HK$5.695 as of press time, with turnover reaching HK$89.7588 million.On the news front, Sino Biopharmaceutical announced...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EURmain","BK4588","LU2272731600.USD","IE00BZ08YR35.GBP","LU2473716301.USD","IE00B5TLWC47.USD","LU1992135472.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","01177","BK1515","PPH","LU2272731865.HKD","LU2322448957.HKD","NBIE","LU2272731782.SGD","MEURmain","VXUS","EUO","BK4585","HK0000165453.HKD","KCAI","XPH","BK1521","BK1589","IBB","FXE","LU1992135399.USD","LU2322448791.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131230465","title":"Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1131230465","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131230465?lang=en_us&edition=fundamental","pubTime":"2026-09-18 09:54","pubTimestamp":1789696466,"startTime":"0","endTime":"0","summary":"A recent industry analysis warns that over the next decade, nearly 90% of biologic drugs losing their market exclusivity will lack a corresponding biosimilar in development, creating a significant...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B5TLWC47.USD","LU1992135472.HKD","LU2272731865.HKD","IBB","LU2322448791.USD","LU2272731782.SGD","BK4588","LU2272731600.USD","159891","LU2473716301.USD","PPH","LU1992135399.USD","XPH","LU2322448957.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188259168","title":"Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14","url":"https://stock-news.laohu8.com/highlight/detail?id=1188259168","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188259168?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:50","pubTimestamp":1789120228,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that the drug registration application for its self-developed denosumab biosimilar, HLX14 (recombinant anti-RANKL fully human...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2272731865.HKD","BK0188","IBB","PPH","IE00B5TLWC47.USD","LU2272731782.SGD","LU2473716301.USD","LU1992135399.USD","LU1992135472.HKD","LU2322448957.HKD","BK1593","BK0060","BK0183","BK0028","BK0012","600196","BK0175","BK1515","BK0096","BK4588","LU2272731600.USD","LU2322448791.USD","BK0187","BK0239","BK4585","02196","XPH","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731600.USD","IBBQ","BK1574","BK4585","BK4588","LU2272731865.HKD","HK0000306685.HKD","HK0000165453.HKD","LU1992135399.USD","LU2322448957.HKD","MEDX","LU2473716301.USD","IBB","LU2272731782.SGD","159992","BK1161","LU1992135472.HKD","LNGR","06978","XPH","IE00B5TLWC47.USD","HK0000320264.USD","LU2322448791.USD","PPH","HK0000320223.HKD","HK0000306701.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTXH","GNMX","TBXU","APXH","NVIB","CURE","PBE","FHLC","CANC","HYLG","MRNY","GDOC","IEIH","LFSC","JHMH","SYNB","MNTL","PSIL","BME","IBBQ","BIB","IBBJ","GSKH","WDNA","RSPH","XPH","MEDX","JDOC","PBPH","PJP","IDNA","GPCR","BBP","LLYX","MDTX","IBB","FBT","IBRN","SURI","PINK","HRTS","FXH","MEDI","PSCH","BBH","CNCR","GNOM","AZNH","PTH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","GDOC","IDNA","PSIL","MEDI","SURI","PSCH","PTH","BIB","BBH","FBT","BME","FTXH","PBE","CNCR","GNOM","LFSC","PJP","SYNB","CANC","JHMH","CURE","GNMX","IBRN","MDTX","PINK","IBBJ","TBXU","IBB","GPCR","FXH","BBP","IBBQ","AZNH","MEDX","XPH","LENZ","SBIO","HYLG","LLYX","MNTL","APXH","RSPH","NVIB","PBPH","WDNA","JDOC","GSKH","FHLC","HRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191429118","title":"Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars","url":"https://stock-news.laohu8.com/highlight/detail?id=1191429118","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191429118?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:00","pubTimestamp":1787194818,"startTime":"0","endTime":"0","summary":"Shares of HENLIUS (02696) climbed nearly 8% during intraday trading, with the stock last up 6.87% at HK$70.05, recording a turnover of HK$16.47 million. The company recently announced a framework...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HK0000306685.HKD","LU2322448957.HKD","HK0000320223.HKD","IE00B5TLWC47.USD","BK4585","XPH","HK0000165453.HKD","BK1161","LU2272731865.HKD","LU2473716301.USD","HK0000320264.USD","02696","LU2322448791.USD","LU1992135472.HKD","IBB","LU2272731600.USD","PPH","LU2272731782.SGD","LU1992135399.USD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492411","title":"BMO starts Exelixis at Market Perform into patent cliff","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492411?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:30","pubTimestamp":1787085023,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durabl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PJP","LU2272731782.SGD","IBB","IE00B5TLWC47.USD","BK4207","PBPH","PTH","IYH","BK4532","XPH","LU1992135472.HKD","IHE","FBT","BBH","BK4139","FXH","FTXH","MEDI","TRUH","MEDX","RXD","BME","PPH","CURE","LU2322448957.HKD","LU1992135399.USD","GSKH","SYNB","RSPH","LU2473716301.USD","AZNH","APXH","LU2322448791.USD","FHLC","USRD","LU2272731600.USD","BMO","JDOC","LU2272731865.HKD","EXEL","BK4588","RXL","TMED","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167771958","title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1167771958","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167771958?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:33","pubTimestamp":1785713585,"startTime":"0","endTime":"0","summary":"AstraZeneca PLC (AZN.US) has been in early-stage discussions about acquiring Bristol-Myers Squibb (BMY.US), a move that could create one of the world's largest pharmaceutical companies, according to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1983299246.USD","LU2237443622.USD","LU2462157665.USD","IE00B3T34201.USD","LU1585245621.USD","LU2125154935.USD","SYNB","LU0128525929.USD","LU0306806265.USD","LU1291159041.SGD","XPH","LU1261432733.SGD","LU1074936037.SGD","LU1868837300.USD","BK4532","LU1718418525.SGD","BK4568","LU0708994859.HKD","LU2133065610.SGD","IE00BSNM7G36.USD","LU1571399168.USD","LU2272731865.HKD","LU0868494617.USD","LU0061475181.USD","LU0029864427.USD","LU0432979614.USD","RXD","LU1323610961.USD","LU1093756325.SGD","FXH","LU2242646821.SGD","IE00B5TLWC47.USD","XBIX","LU1670711123.USD","IEHS","LU2360032135.SGD","LU2125154778.USD","LU0267386448.USD","LU2322448791.USD","CURE","IHE","LU0456855351.SGD","LU0310800379.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4534","LU0225284248.USD","LU1868836757.USD","LU0289739699.SGD","IE00BFXG1179.USD","LU2417539215.USD","MEDI","IE00BFTCPJ56.SGD","LU2272731782.SGD","BK4588","LU0114720955.EUR","JHMH","LU1868836591.USD","LU1883839398.USD","LU2236285917.USD","BK4559","LU0306807586.USD","LU0237698245.USD","LU2596442595.SGD","AZNH","LU1267930573.SGD","LU1670710661.SGD","LU2089984988.USD","LU2272731600.USD","AZN","LU2237443382.USD","BK4007","LU0225771236.USD","PILL","FTXH","LU0058720904.USD","LU1032466523.USD","LU1670710588.SGD","LU1868836914.USD","LU2237443895.HKD","LU1093756168.USD","FHLC","IE0002141913.USD","IE00B2B36J28.USD","LU0321505868.SGD","LU2237443465.HKD","LU1989771016.USD","LU2242652126.USD","LU2468319806.SGD","PPH","LU0109394709.USD","LU0882574055.USD","LU2456880835.USD","LU1430594728.SGD","LU2237443549.SGD","LU2322448957.HKD","BK4585","LU2237443978.SGD","IE00BJT1NW94.SGD","LU0985481810.HKD","LU0321505439.SGD","LU1829250122.USD","RXL","LU1868837136.USD","LU1992135399.USD","LU2473716301.USD","LU0096364046.USD","LU0320765992.SGD","LU1992135472.HKD","BK4581","BMY","LU1670711040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122606361","title":"HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1122606361","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122606361?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:32","pubTimestamp":1783503169,"startTime":"0","endTime":"0","summary":"HENLIUS (ASX: 02696) has announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1 clinical study of its self-developed cetuximab injection...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HK0000320264.USD","LU2322448791.USD","HK0000306701.USD","PPH","LU2322448957.HKD","BK4585","HK0000165453.HKD","LU1992135472.HKD","BK1161","LU2473716301.USD","HK0000306685.HKD","02696","IE00B5TLWC47.USD","LU2272731600.USD","LU1992135399.USD","LU2272731865.HKD","XPH","LU2272731782.SGD","IBB","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":-0.0551},{"period":"3month","weight":0.0094},{"period":"6month","weight":0.2224},{"period":"1year","weight":0.4226},{"period":"ytd","weight":0.1943}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the \"index\"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index (\"S&P TMI\").","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.007115},{"month":2,"riseRate":0.5,"avgChangeRate":0.005226},{"month":3,"riseRate":0.35,"avgChangeRate":-0.008876},{"month":4,"riseRate":0.55,"avgChangeRate":0.010219},{"month":5,"riseRate":0.7,"avgChangeRate":0.008516},{"month":6,"riseRate":0.6,"avgChangeRate":0.067402},{"month":7,"riseRate":0.666667,"avgChangeRate":0.017952},{"month":8,"riseRate":0.571429,"avgChangeRate":0.012588},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.015642},{"month":10,"riseRate":0.65,"avgChangeRate":-0.004052},{"month":11,"riseRate":0.7,"avgChangeRate":0.032588},{"month":12,"riseRate":0.55,"avgChangeRate":0.007413}],"exchange":"ARCA","name":"Spdr S&P Pharmaceuticals Etf","nameEN":"Spdr S&P Pharmaceuticals Etf"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spdr S&P Pharmaceuticals Etf(XPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spdr S&P Pharmaceuticals Etf(XPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spdr S&P Pharmaceuticals Etf,XPH,Spdr S&P Pharmaceuticals Etf股票,Spdr S&P Pharmaceuticals Etf股票老虎,Spdr S&P Pharmaceuticals Etf股票老虎国际,Spdr S&P Pharmaceuticals Etf行情,Spdr S&P Pharmaceuticals Etf股票行情,Spdr S&P Pharmaceuticals Etf股价,Spdr S&P Pharmaceuticals Etf股市,Spdr S&P Pharmaceuticals Etf股票价格,Spdr S&P Pharmaceuticals Etf股票交易,Spdr S&P Pharmaceuticals Etf股票购买,Spdr S&P Pharmaceuticals Etf股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spdr S&P Pharmaceuticals Etf(XPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spdr S&P Pharmaceuticals Etf(XPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}